All In Biotech

NDA 217766 · Long Grove Pharms

Vasopressin In Sodium Chloride 0.9%

Vasopressin · Intravenous

Last checked: Nov 20, 2026Latest source record: Jul 11, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Jul 11, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

331

81 Phase 3, 37 recruiting

FAERS reports

4,378

4,221 serious, 1,722 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 17, 2025.

Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )

Mechanism: Vasopressin causes vasoconstriction by binding to V 1 receptors on vascular smooth muscle coupled to the Gq/11-phospholipase C-phosphatidyl-inositol-triphosphate pathway, resulting in the release of intracellular calcium. In addition, vasopressin stimulates antidiuresis via stimulation of V 2 receptors which are coupled to adenyl cyclase.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • VASOPRESSIN IN SODIUM CHLORIDE 0.9% · VASOPRESSIN 40UNITS/100ML (0.4UNITS/ML) · SOLUTION, INTRAVENOUS · Prescription
  • VASOPRESSIN IN SODIUM CHLORIDE 0.9% · VASOPRESSIN 50UNITS/50ML (1UNIT/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INTRAVENOUS · Discontinued
  • VASOPRESSIN IN SODIUM CHLORIDE 0.9% · VASOPRESSIN 20UNITS/100ML (0.2UNITS/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vasopressin" as an intervention, any sponsor and status, largest first.

All 331 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,358
  • off label use551
  • hypotension509
  • cardiogenic shock427
  • multiple organ dysfunction syndrome423
  • sepsis413
  • condition aggravated401
  • toxicity to various agents342
  • acute kidney injury340
  • stress319
  • vomiting319
  • abdominal pain301

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200414
200517
200628
200732
200826
200943
201042
2011134
201271
201336
201488
201567
201693
2017144
2018164
2019169
2020387
2021615
2022415
2023535
2024449
2025512
2026297

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,660 on PubMed

Sponsor: Long Grove Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.